Professor Ashok Venkitaraman
Ursula Zoellner Professor; Director, MRC Cancer Cell Unit
Professor Ashok Venkitaraman is pleased to consider applications from prospective PhD students.
MRC Cancer Cell Unit and Department of Oncology
Cancer biology and in vivo models
Experimental therapeutics / drug discovery
Human cancer cells almost always contain abnormal chromosomes, yet the connections between chromosomal instability and carcinogenesis are poorly understood. Our laboratory aims not only to understand how cells maintain normal chromosome structure and number, and why maintenance should break down in cancer cells, but also to translate this knowledge to improvements in cancer diagnosis and treatment. We employ a wide range of approaches from molecular cell biology and somatic cell genetics, to structural biology, biophysics, imaging and chemical biology.
We actively translate molecular insights from our studies to clinical practice. In particular, we participate in The Cambridge Molecular Therapeutics Programme, a multidisciplinary effort that aims to pioneer innovative new approaches for the discovery and early clinical development of small molecule drugs against cancer.
Skoulidis F, Cassidy L, Pisupati V, Jonasson J, Eyfjord J, Kerreth F, Lim M, Olive K, Tuveson D, Venkitaraman AR (2010), “Germline Brca2 heterozygosity promotes KrasG12D-driven carcinogenesis in a murine model of familial pancreatic cancer”, Cancer Cell 18:499–505
Garnett M, Mansfeld J, Godwin C, Matsusaka T, Wu J, Russell P, Pines J, Venkitaraman AR (2009), “UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit”, Nature Cell Biol 11:1363–69
Ayoub NA, A D, Devaprasath JA, Bernal AR, Venkitaraman (2008), “HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response”, Nature 453: 682 6: